Big Pharma’s Favorite Democrats

Three House Democrats working to kill legislation to control prescription drug prices raked in roughly $1.6 million from pharma donors — and the top aide for one of them is now a Big Pharma lobbyist.

U.S. Representative Kurt Schrader (D-OR) speaking at a press

US Representative Kurt Schrader (D-OR) speaking at a press conference in Washington, DC, 2019. (Michael Brochstein / SOPA Images / LightRocket via Getty Images)


The three conservative Democratic lawmakers threatening to kill their party’s drug pricing legislation have raked in roughly $1.6 million of campaign cash from donors in the pharmaceutical and health products industries. One of the lawmakers is the House’s single largest recipient of pharmaceutical industry campaign cash this election cycle, and another lawmaker’s immediate past chief of staff is now lobbying for drugmakers.

The threat from Democratic Representatives Kurt Schrader (OR), Scott Peters (CA), and Kathleen Rice (NY) comes just as the pharmaceutical industry’s top lobbying group announced a seven-figure ad campaign to vilify the Democratic legislation that aims to lower the cost of medicines for Americans now facing the world’s highest prescription drug prices.

At issue is House Democrats’ initiative to let Medicare use its bulk purchasing power to negotiate lower prescription drug prices. That power — which is used by other industrialized countries to protect their citizens from exorbitant prices — has been promised by Democrats for years, and party leaders have been planning to include it as part of their sprawling $3.5 trillion infrastructure reconciliation effort.

This article is for subscribers only. Please login or subscribe to access our full archives and beautiful print and digital magazine starting at just $3 a month.